ANGPT2 and metastatic colorectal cancer: It has been reported that patients with advanced metastatic colorectal cancer had high serum levels of ANGPT2, and Bevacizumab therapy reduced these levels, suggesting that it may play a role in modulating its effect on VEGF levels [46].